NCT06633042View on ClinicalTrials.gov

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

October 12, 2025

Study Completion Date

December 12, 2025

Conditions
Autoimmune Disease
Interventions
DRUG

Universal BCMA-CD19 CART

1.0-4.0×10\^6 CAR-T cells/kg

Sponsors
All Listed Sponsors
collaborator

Wenzhou Medical University Affiliated Ophthalmology Hospital

UNKNOWN

lead

Bioray Laboratories

INDUSTRY

NCT06633042 - The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD | Biotech Hunter | Biotech Hunter